ClinicalTrials.gg
RecruitingNCT06107764Updated Aug 20, 2026

Cerebellar Modulation of Cognition in Psychosis

An interventional study of intermittant theta burst stimulation (iTBS) and continuous theta burst stimulation (cTBS) in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder I, sponsored by Mclean Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Mclean Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Schizophrenia by Mclean Hospital — 4 open to participants now, 4 under way, 1 of them phase 3. Schizophrenia · Mclean Hospital.

Planned enrollment
4th of 14
95 · median 48
Started
2024
with 2 others
No phase
8 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Schizophrenia by Mclean Hospital, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 with no phase, and was the 14th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 15 studies in Schizophrenia by Mclean Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Schizophrenia by Mclean Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks).

Participants will be asked to perform cognitive tasks (problem-solving) and undergo brain scans before and after transcranial magnetic stimulation (TMS). TMS is a way to non-invasively change brain activity. Forms of TMS are FDA-approved to treat depression and obsessive compulsive disorder. In this study, we will use a different form of TMS to temporarily change brain activity to observe how that changes speed in problem-solving.

Read the detailed description

Psychotic disorders including schizophrenia, bipolar disorder, and related illnesses are severe, debilitating, and often fatal. Cognitive impairments in psychosis are among the leading predictors of disability and poor quality of life; despite this, there are no first-line interventions to target these symptoms.

This trial will test the hypothesis that cognitive performance in these disorders is modifiable and specifically that it can be modified non-invasively. Transcranial magnetic stimulation (TMS) is a neuromodulation technique that utilizes magnets to alter brain activity non-invasively. TMS has received FDA approval as a therapeutic intervention for multiple psychiatric disorders. In this study, we will use different forms of TMS to modulate a specific brain circuit and we will measure the outcomes of this circuit manipulation. These outcomes include performance on cognitive tests and also changes to the circuit itself that we can measure using magnetic resonance imaging (MRI).

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder I
  • Psychosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-55 years
  • Diagnosis of a psychotic disorder (i.e. schizophrenia or schizoaffective disorder or bipolar disorder type I)
  • Must be able to read, speak and understand English
  • Must be judged by study staff to be capable of completing the study procedures
  • Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens.

Exclusion criteria

Exclusion Criteria:

  • Diagnostic and Statistical Manual 5 diagnosis of moderate substance use disorder within the past month
  • Conditions that might result in increased risks of side effects or complications from rTMS or MRI, including:

    • Intracranial pathology from a known genetic disorder (e.g., Neurofibromatosis 1, tuberous sclerosis) or from acquired neurologic disease (e.g. stroke, tumor), cerebral palsy, history of severe head injury, or significant dysmorphology;
    • History of fainting spells of unknown or undetermined etiology that might constitute seizures
    • History of multiple seizures or diagnosis of epilepsy
    • Any progressive (e.g., neurodegenerative) neurological disorder such as multiple sclerosis or Parkinson's disease
    • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
    • Metal implants (excluding dental fillings) unless cleared by the responsible covering MD (i.e. MRI compatible joint replacement)
    • Pacemaker
    • Implanted medication pump
    • Vagal nerve stimulator
    • Deep brain stimulator or transcutaneous electric nerve stimulation unit
    • Ventriculo-peritoneal shunt
    • Signs of increased intracranial pressure
    • Intracranial lesion
    • History of head injury resulting in prolonged loss of consciousness (>15minutes) or neurological sequelae
    • Pregnancy: All participants capable of becoming pregnant will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
95 participants (estimated)

Study arms

  • Active comparator
    Intermittent theta burst stimulation (iTBS)

    Participants complete MRI scanning and cognitive testing followed by rTMS (iTBS pattern) followed by repeat cognitive testing and MRI scanning

    Device: intermittant theta burst stimulation (iTBS)

  • Active comparator
    continuous theta burst stimulation (cTBS)

    Participants complete MRI scanning and cognitive testing followed by rTMS (cTBS pattern) followed by repeat cognitive testing and MRI scanning

    Device: continuous theta burst stimulation (cTBS)

  • Sham comparator
    sham rTMS

    Participants complete MRI scanning and cognitive testing followed by sham rTMS followed by repeat cognitive testing and MRI scanning

    Device: sham rTMS

Interventions

  • Deviceintermittant theta burst stimulation (iTBS)

    iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.

  • Devicecontinuous theta burst stimulation (cTBS)

    cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses

  • Devicesham rTMS

    sham rTMS does not deliver a significant change in magnetic field strength

06

What researchers measure

Primary outcomes

  1. BACS Symbol Coding test

    The BACS Symbol coding test is a test of information processing speed

    Time frame: eight minutes before TMS and one minute after TMS on each of the three TMS visit days

  2. BACS Digit Sequence test

    The BACS digit sequence test is a test of working memory performance

    Time frame: five minutes before TMS and four minutes after TMS on each of the three TMS visit days

  3. functional Magnetic Resonance Imaging

    resting-state (task free) functional connectivity

    Time frame: fifteen minutes before TMS and nine minutes after TMS on each of the three TMS visit days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2029, 65 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 65 months is above that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 30, 2023
StartActual
Jul 31, 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06107764
Lead sponsor
Mclean Hospital
Responsible party
Kathryn Eve Lewandowski (Associate Professor of Psychiatry, McLean Hospital, Mclean Hospital) — Principal investigator
First posted
Oct 30, 2023
Start date
Jul 31, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion